Contac

Contac developed as a branded over-the-counter remedy for common cold symptoms. In China, the brand became widely known through the Chinese name 康泰克, while later products were commonly described as 新康泰克, or “new Contac.” The brand's historical development is closely tied to changes in the regulation of decongestant ingredients and to the reformulation of combination cold medicines. The most important documented turning point concerns phenylpropanolamine. Earlier Contac products in China were associated with this decongestant. Around 2000, safety concerns and regulatory action concerning phenylpropanolamine resulted in withdrawal or suspension of affected products in China and other markets. The change meant that the earlier formulation could no longer serve as the basis for ordinary retail distribution. Later products using the 新康泰克 name were introduced with alternative active ingredients and were marketed as updated cold-relief medicines. The new-generation product became associated with combination formulations intended to address more than one symptom at a time. Product information for versions sold in China has described active ingredients such as pseudoephedrine, a nasal decongestant, and chlorpheniramine, an antihistamine; formulations can change, so the package insert and current authorization remain the controlling sources. The products are intended for temporary symptomatic relief and are not substitutes for medical evaluation when symptoms are severe, persistent or atypical. The brand's presence in China has primarily been linked to pharmacy-based self-medication and the broader consumer-health market. Its commercial identity has remained stronger than the publicly documented corporate history available for this entry. Historical references associate Chinese distribution and manufacture with multinational pharmaceutical businesses, but ownership and operating arrangements may have changed over time. No current corporate parent, headquarters or official website is confirmed here. Because the supplied material contains no authoritative corporate record, the encyclopedia does not assign a definitive founding year or current owner. It also does not treat the brand as internationally famous: Contac has had recognition in more than one market, but 新康泰克 is chiefly identified with China. The principal historical lesson of the brand is the importance of formulation changes, ingredient-level regulation and clear labeling in the OTC cold-medicine sector.

1. 2000Regulatory withdrawal of phenylpropanolamine-containing products

   Regulatory action concerning phenylpropanolamine affected the earlier 康泰克 product generation in China and created the need for reformulated products marketed under the 新康泰克 name.

An OTC cold-and-flu brand positioned around short-term, multi-symptom relief, particularly nasal congestion and other common upper-respiratory symptoms.

• 新康泰克 sustained-release cold capsulesOTC cold and flu medicine

  A branded oral cold remedy associated with temporary relief of multiple upper-respiratory symptoms. Chinese versions have been identified with decongestant-and-antihistamine combinations, including pseudoephedrine-based formulations in some product presentations. The exact ingredients, strength, age suitability, warnings and dispensing conditions must be checked against the current package insert and regulatory label.

• Earlier 康泰克 productsOTC cold and flu medicine

  The earlier Chinese Contac generation was associated with phenylpropanolamine-containing cold medicine. Following regulatory concerns and market withdrawal around 2000, these products were superseded by reformulated offerings. They are included as a historical product generation, not as a current recommendation or confirmed active product.

• 2000Transition from the earlier 康泰克 formulation to 新康泰克Generation change

  Safety and regulatory concerns surrounding phenylpropanolamine-containing cold medicines affected the earlier Contac product generation in China.

  What changed. The earlier formulation was withdrawn or suspended, and later Contac products were marketed with alternative active-ingredient combinations.

  Aftermath. The 新康泰克 name became associated with the reformulated generation, while the original 康泰克 formulation remained a historical product rather than an ordinary current retail product.

• 2000China removed phenylpropanolamine-containing cold medicines from the market

  Chinese regulatory action concerning phenylpropanolamine-containing medicines affected the original Contac product line and led to the distinction between earlier 康泰克 products and later 新康泰克 formulations. This entry does not identify a single verified news URL for the action.

  RegulationProduct generation